Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Molecular cancer therapeutics·2026
Same author

Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids.

SLAS discovery : advancing life sciences R & D·2025
Same author

Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation.

bioRxiv : the preprint server for biology·2025
Same author

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Cancer research communications·2025

Related Experiment Video

Updated: May 24, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Searching for molecular targets in sarcoma.

Beverly A Teicher1

  • 1Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA. Beverly.Teicher@nih.gov

Biochemical Pharmacology
|March 6, 2012
PubMed
Summary

Sarcomas are rare cancers originating from mesenchymal stem cells. Understanding sarcoma genetics, including mutations and amplifications, is key to developing targeted therapies for these diverse tumors.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Related Experiment Videos

Last Updated: May 24, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Area of Science:

  • Oncology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Sarcomas constitute approximately 1% of all cancers and exhibit significant heterogeneity.
  • These tumors arise from mesenchymal stem cells, which are pluripotent and can differentiate into various cell types.
  • Sarcomas affect all age groups, with their origin often linked to genetic alterations in mesenchymal stem cells.

Purpose of the Study:

  • To review the current understanding of sarcoma genetics.
  • To identify frequently mutated, amplified, and upregulated genes in various sarcoma subtypes.
  • To highlight the potential for developing targeted therapies based on genetic profiles.

Main Methods:

  • Review of existing literature on sarcoma genetics.
  • Analysis of gene mutations, amplifications, and expression patterns across different sarcoma types.
  • Classification of sarcomas based on genetic characteristics, such as chromosomal translocations and complex genetics.

Main Results:

  • Sarcomas can be broadly categorized into those with chromosomal translocations and those with complex genetics.
  • Key mutated genes include TP53, NF1, and PIK3CA; amplified genes include CDK4 and MDM2; and upregulated genes include MUC4 and CD24.
  • Specific genetic alterations are associated with particular sarcoma subtypes, while others are common across multiple types.

Conclusions:

  • Detailed knowledge of sarcoma genetics is rapidly advancing.
  • Understanding these genetic alterations is crucial for the development of novel, subtype-specific therapeutic strategies.
  • Targeted therapies hold promise for improving outcomes in patients with sarcoma.